Abstract 606P
Background
Cutaneous melanoma is considered a rare but lethal cancer among Asians. Prognosis is generally worse with high rates of recurrences and mortality. Clinical presentations show striking differences with cutaneous melanoma among Caucasian. Acral lentiginous and nodular melanoma are the most common subtypes among Asian. Patterns of mutations and molecular alterations and the association with prognosis are not yet known among melanoma patients in Indonesia. This study aims to analyze association between BRAF dan NRAS mutations with overall survival of melanoma patients in Indonesia.
Methods
DNA from formalin-fixed paraffin embedded tissues from melanoma patients were extracted. PCR and pyrosequencing were performed to detect mutations in the BRAF dan NRAS genes.
Results
Of 51 melanoma patients, 44 patients (86.3%) were diagnosed with Breslow thickness more than 4 mm (T4). In the primary cutaneous melanoma lesions, 33 (67%) patients had ulceration, 47 patients (92.2%) had diameter more than 6 mm, and 30 patient (58.2%) had positive regional lymph nodes. In this study, BRAF mutations were found in 26 patients (56%) and NRAS mutations were found in 5 patients (9.8%). BRAF mutations were found in older age than 65 years although the difference was not significant (OR 2.205, 95%CI: 0.558-8.717, P=0.259). BRAF mutations were associated with significantly lower overall survivals compared to wild-type (median survivals were 18 vs 34 months, P=0.042). Although patients with NRAS mutations had shorter survival, the difference was not statistically significant (P=0.120). Patients with BRAF or NRAS were associated with significant lower overall survivals compared to those with wild-type (Median survivals were 19 vs 35 months, P=0.044).
Conclusions
BRAF and / or NRAS mutations were associated with shorter survival among cutaneous melanomas in Indonesia with predominant subtypes of acral lentiginous and nodular melanomas. Larger study from Asian population is required to extend our finding to establish a prognostic marker as well as a potential targeted treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Gadjah Mada University.
Funding
Gadjah Mada University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract